Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol

被引：6
|
作者：
Seidah, Nabil G. [1 ]
机构：
[1] Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ, Canada
来源：
NATURE STRUCTURAL & MOLECULAR BIOLOGY | 2017年 / 24卷 / 10期
关键词：
PROPROTEIN; MUTATIONS; BINDING; DEGRADATION; PEPTIDE;
D O I：
10.1038/nsmb.3471
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
PCSK9 enhances LDL cholesterol (LDL-c) levels by escorting the liver LDL receptor (LDLR) to endosomes and lysosomes for degradation. PCSK9 monoclonal antibodies and RNA-antisense formulations are effective in reducing LDL cholesterol in patients. The recent structural identification of a novel pocket in PCSK9 paves the way to the future development of orally active small-molecule hypocholesterolemic drugs.
引用
收藏
页码：785 / 786
页数：2
相关论文
共 50 条
  • [1] Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
    Nabil G Seidah
    Nature Structural & Molecular Biology, 2017, 24 : 785 - 786
  • [2] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [3] PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk Great Expectations
    Waters, David D.
    Hsue, Priscilla Y.
    CIRCULATION RESEARCH, 2015, 116 (10) : 1643 - 1645
  • [4] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [5] PCSK9—an exciting target for reducing LDL-cholesterol levels
    D. John Betteridge
    Nature Reviews Endocrinology, 2013, 9 : 76 - 78
  • [6] LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors
    Luscher, Thomas F.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1337 - 1340
  • [7] The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
    Piper, Derek E.
    Jackson, Simon
    Liu, Qiang
    Romanow, William G.
    Shetterly, Susan
    Thibault, Stephen T.
    Shan, Bei
    Walker, Nigel P. C.
    STRUCTURE, 2007, 15 (05) : 545 - 552
  • [8] Evolocumab (Repatha) - A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1479): : 140 - 141
  • [9] PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Luquero, Aureli
    Badimon, Lina
    Borrell-Pages, Maria
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [10] PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
    Wang, Yan
    Liu, Zhao-Peng
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 165 - 176
12345